在APOEε4载体中为阿尔茨海默病提供保护的非洲原产哈普洛型:探索潜在的机制
Luciana Bertholim-Nasciben1, Karen Nuytemans1,2, Derek Van Booven1
1John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
bioRxiv : the preprint server for biology
|November 1, 2024
概括
一种新发现的非洲基因变体rs10423769_A显著降低了携带APOEε4基因的个体患阿尔茨海默病 (AD) 的风险. 这种保护作用凸显了多元祖先在阿尔茨海默病研究中的重要性.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
背景情况:
- 阿波利波蛋白E (APOE) ε4基因是阿尔茨海默病 (AD) 的主要遗传风险因素.
- 大约50%的阿兹海默症患者至少携带一个APOEε4等位基因,这凸显了其显著的影响.
研究的目的:
- 为了研究APOEε4与非洲特异型之间的一种保护性相互作用,rs10423769_A.
- 阐明这种保护作用背后的遗传和分子机制.
主要方法:
- 利用短读和长读测序来分析rs10423769变种及其周围的基因组区域.
- 研究了与保护性单双型相关的结构和DNA甲基化差异.
- 分析了扩展变量数并列重复 (VNTR) 与保护性单元型的关联.
主要成果:
- 鉴定了rs10423769_A作为APOEε4同胞体中抗阿尔茨海默病风险的保护变体,降低了约75%的风险.
- 保护变体位于19号染色体上细分重复区域的独特单元型中,靠近妊娠特异性β-1糖蛋白基因 (PSG).
- 发现了显著的结构和DNA甲基化差异,以及扩展的VNTR与MEF2结合动机,与保护性单元型相关.
结论:
- rs10423769_A基因组代表了一种古老的,非洲起源的,在APOEε4载体中对AD的保护因子.
- 这一发现为阿尔茨海默氏症的发病过程提供了新的见解,并强调了在遗传研究中对多样化的祖先种群的关键需求.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
18.9K
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.8K
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Genome-wide Association Studies-GWAS
12.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.5K
Genetic Lingo
101.3K
Overview
101.3K
